ErythrobLastosis fetalis can be prevented if the mother is injected at parturition, with an antibody called
**Core Concept**
Erythroblastosis fetalis is a condition that occurs when there is an Rh blood type incompatibility between the mother and the fetus. This incompatibility leads to the production of antibodies against the Rh-positive blood cells, which can cause hemolysis of the fetal red blood cells. The condition is a significant cause of fetal anemia and can lead to severe complications if left untreated.
**Why the Correct Answer is Right**
The injection of Rh immune globulin (RhIg) at parturition is a preventive measure to avoid the formation of antibodies against the Rh-positive blood cells. RhIg works by neutralizing any remaining fetal Rh-positive red blood cells that may have entered the maternal circulation, thereby preventing the activation of the immune system and the production of anti-Rh antibodies. This treatment is crucial in preventing the recurrence of erythroblastosis fetalis in subsequent pregnancies.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect as it does not specify the correct antibody used to prevent erythroblastosis fetalis. While there are other antibodies that can be used to treat various conditions, RhIg is the specific antibody used to prevent this condition.
**Option B:** This option is incorrect as it does not provide a clear answer and does not specify the correct antibody used to prevent erythroblastosis fetalis.
**Option C:** This option is incorrect as it does not specify the correct antibody used to prevent erythroblastosis fetalis.
**Clinical Pearl / High-Yield Fact**
RhIg should be administered to all Rh-negative women at 28 weeks of gestation and within 72 hours of delivery to prevent the formation of anti-Rh antibodies and the recurrence of erythroblastosis fetalis in subsequent pregnancies.
**Correct Answer: D. Rh immune globulin**